期刊文献+

抑郁焦虑障碍靶症状个体差异临床治疗意义

Clinical significance of individual differences of the depression and anxiety target symptoms
下载PDF
导出
摘要 目的针对抑郁焦虑障碍患者不同的靶症状,选用不同类型的抗抑郁药物进行治疗,发挥其治疗最佳效应,减少不良反应,提高临床疗效。方法采用临床随机对照研究的方法,将87例符合ICD-10《精神与行为障碍分类》抑郁障碍、焦虑障碍诊断标准,且排除精神病性抑郁、难治性抑郁和强迫障碍、创伤后应激障碍等的患者;随机分为研究组和对照组,研究组针对患者不同的靶症状,依据《中国精神障碍治疗指南》选用相应的抗抑郁药物进行治疗,对照组进行常规治疗。两组分别于治疗2周、6周、12周后进行简明精神症状自评量表(SCL-90)及临床总体印象量表(CGI)、药物副反应量表(SERS)评定。结果治疗2周后两组SCL-90及CGI评分较治疗前差异均有统计学意义(P<0.05),组间比较差异有统计学意义(P<0.01);治疗12周后研究组CGI评分的减分率为69.4%,对照组CGI评分减分率为61.4%,两组比较差异有统计学意义(P<0.05);两组药物副反应量表(SERS)评分常见副反应程度比较,差异有统计学意义(P<0.05)。结论抑郁焦虑障碍靶症状可能是患者个体差异的外在表现,针对临床靶症状治疗,疗效可靠,药物不良反应小,治疗依从性高。 Objective According to different target symptoms in patients with depression and anxiety disorder, selected antidepressant therapy for different types to play the best treatment effect, reduce adverse reactions, improve clinical efficacy. Methods By the method of randomized controlled clinical study, 87 patients with ICD-10 "mental and be- havioural disorders classification" depression, anxiety disorder diagnosis standard, and the exclusion of psychotic de- pression, treatment resistant depression and obsessive-compulsive disorder, post-traumatic stress disorder patients; were randomly divided into study group and control group, the study group at the target symptoms of the patients were treated according to different"treatment of Chinese mental disorder guide" the antidepressant drugs, the control group was given conventional treatment. In two groups after 2 weeks, 6 weeks, 12 weeks effect, brief psychiatric Checklist (SCL-90) and Clinical Global Impression Scale (CGI), treatment Emergent Symptom Scale (SERS) were assess. Results After 2 weeks treatment, the SCL-90 and CGI of two groups were lower than that before treatment were significantly different (P 〈 0.05), the difference between group comparison was very significant (P 〈 0.01); after 12 weeks treatment study group CGI score reduction rate was 69.4%, control group CGI score reduction rate was 61.4%, had significant difference(P 〈 0.05); Adverse drug reaction seale(SERS) score between the two grbups was significant(P 〈 0.05). Conclusion Depression and anxiety disorder symptoms may be a manifestation ofthe target individual difference of the patient, the clinical targetsymptoms, efficacy, adverse drug reaction is small, high compliance oftreatment.
出处 《中国现代医生》 2014年第13期28-30,34,共4页 China Modern Doctor
关键词 抑郁焦虑障碍 靶症状 依从性 Depression and anxiety disorders Target symptoms Compliance
  • 相关文献

参考文献11

二级参考文献137

  • 1司天梅,舒良,吉中孚,李惠春,陶明,唐永怡,李晓光,季建林,史以玉,王崇顺,梅其一,欧红霞,翁正,王铭,端义扬,秦晓霞,金雪光.文拉法辛缓释剂治疗抑郁症的开放性研究[J].中华精神科杂志,2006,39(2):85-89. 被引量:38
  • 2江开达,苏晖,徐一峰,李飞,刘晓华,刘义兰,潘桂花.文拉法辛缓释剂和氟西汀治疗首发抑郁症的对照研究[J].上海精神医学,2007,19(1):15-18. 被引量:7
  • 3[1]Bland RC, Newman SC, Om H. Lifetime prevalence of psychiatric disorder in edmonton. Acta Psychiatrica Scandinavica, 1988, 77(Suppl 338) :24~32 被引量:1
  • 4[2]Turner SM, Jacob RG, Beidel DC, et al. Fluoxetine treatment of obsessive complsive disorder. Journal of Clinical Psychopharmacology,1985, 5 : 207 ~212 被引量:1
  • 5[5]Jenike MA, Micheal A, Lywn Buttolpn Lee Bear, et al. Open trail of flouxetine in obsessive complsive disorder. Am J Psychiatry, 1989,146: 909 被引量:1
  • 6[8]Montgomery SA, Mclntyre A, Osterheider M, et al. A double-blind,place-controlled study of fluoxetine in patient DMS-Ⅲ -R obsessive complsive disorder. European Neuropsychopharmacology, 1993, 3 :143 ~ 152 被引量:1
  • 7Gorman JM. Treating generalized anxiety disorder. J Clin Psychiatry,2003,64 (Suppl, 2): 24 -29. 被引量:1
  • 8Thase ME. Effectiveness of antidepressants:comparative remission rates.J Clin Psychiatry,2003,64(Suppl,2) :3-7. 被引量:1
  • 9Keck PE, McElroy SL. New approaches in managing bipolar depression.J Clin Psychiatry,2003,64 (Suppl, 1): 13-18. 被引量:1
  • 10Lam RW, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depressiong focus on Metaanalyses. Can J Psychiatry ,2004,49 (Suppl, 1): 17-26. 被引量:1

共引文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部